TY - JOUR
T1 - Neural Correlates of Three Promising Endophenotypes of Depression
T2 - Evidence from the EMBARC Study
AU - Webb, Christian A.
AU - Dillon, Daniel G.
AU - Pechtel, Pia
AU - Goer, Franziska K.
AU - Murray, Laura
AU - Huys, Quentin J.M.
AU - Fava, Maurizio
AU - McGrath, Patrick J.
AU - Weissman, Myrna
AU - Parsey, Ramin
AU - Kurian, Benji T.
AU - Adams, Phillip
AU - Weyandt, Sarah
AU - Trombello, Joseph M.
AU - Grannemann, Bruce
AU - Cooper, Crystal M.
AU - Deldin, Patricia
AU - Tenke, Craig
AU - Trivedi, Madhukar
AU - Bruder, Gerard
AU - Pizzagalli, Diego A.
N1 - Funding Information:
The EMBARC study was supported by the National Institute of Mental Health of the National Institutes of Health under award numbers U01MH092221 (Trivedi, M.H.) and U01MH092250 (McGrath, P.J., Parsey, R.V., Weissman, M. M.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Drs. Webb, Dillon and Pizzagalli were supported by NIMH F32 MH099801, R00 MH094438, and R01 MH068376, respectively. Valeant Pharmaceuticals donated the Wellbutrin XL used in the study. This work was supported by the EMBARC National Coordinating Center at UT South-western Medical Center to Madhukar H. Trivedi, M.D., Coordinating PI, and the Data Center at Columbia and Stony Brook Universities. Dr Kurian has received grant support from the following additional sources: Targacept, Inc.; Pfizer, Inc.; Johnson & Johnson; Evotec; Rexahn; Naurex; and Forest Pharmaceuticals. Dr Trombello owns Merck and J&J stock. Dr Trivedi is or has been an advisor/consultant to: Abbott Laboratories, Inc., Abdi Ibrahim, Akzo (Organon Pharmaceuticals Inc.), Alkermes, AstraZeneca, Axon Advisors, Bristol-Myers Squibb Company, Cephalon, Inc., Cerecor, Concert Pharmaceuticals, Inc., Eli Lilly & Company, Evotec, Fabre Kramer Pharmaceuticals, Inc., Forest Pharmaceuticals, GlaxoSmithKline, Janssen Global Services, LLC, Janssen Pharmaceutica Products, LP, Johnson & Johnson PRD, Libby, Lundbeck, Meade Johnson, MedAvante, Medtronic, Merck, Mitsubishi Tanabe Pharma Development America, Inc., Naurex, Neuronetics, Otsuka Pharmaceuticals, Pamlab, Parke-Davis Pharmaceuticals, Inc., Pfizer Inc., PgxHealth, Phoenix Marketing Solutions, Rexahn Pharmaceuticals, Ridge Diagnostics, Roche Products Ltd., Sepracor, SHIRE Development, Sierra, SK Life and Science, Sunovion, Takeda, Tal Medical/Puretech Venture, Targacept, Transcept, VantagePoint, Vivus, and Wyeth-Ayerst Laboratories. In addition, he has received research support from: Agency for Healthcare Research and Quality (AHRQ), Corcept Therapeutics, Inc., Cyberonics, Inc., National Alliance for Research in Schizophrenia and Depression, National Institute of Mental Health, National Institute on Drug Abuse, Novartis, Pharmacia & Upjohn, Predix Pharmaceuticals (Epix), and Solvay Pharmaceuticals, Inc. For a comprehensive list of lifetime disclosures of Dr Fava, see http://mghcme.org/faculty/faculty-detail/maurizio_fava. Over the past 3 years, Dr McGrath has received research support from the National Institute of Mental Health, the New York State Department of Mental Hygiene, the Research Foundation for Mental Hygiene (New York State), F. Hoffman-LaRoche, Ltd., Naurex Pharmaceuticals, Forest Research and Sunovion Pharmaceuticals. In the past 3 years, Dr Weissman received funding from the National Institute of Mental Health, the National Institute on Drug Abuse, the National Alliance for Research on Schizophrenia and Depression, the Sackler Foundation, and the Templeton Foundation; and received royalties from the Oxford University Press, Perseus Press, the American Psychiatric Association Press and MultiHealth Systems. Dr Weissman declares that none of these present a conflict of interest. Dr Grannemann declares that, except for income received from a primary employer and the above grant (U01MH092221), no financial support or compensation has been received from any individual or corporate entity over the past 3 years for research or professional service and there are no personal financial holdings that could be perceived as constituting a potential conflict of interest. Over the past 3 years, Dr Pizzagalli has received honoraria/consulting fees from Advanced Neuro Technology North America, AstraZeneca, Otsuka America Pharmaceutical, Pfizer, and Servier for activities unrelated to this project. The remaining authors declare no conflict of interest.
Publisher Copyright:
© 2016 American College of Neuropsychopharmacology. All rights reserved.
PY - 2016/1/1
Y1 - 2016/1/1
N2 - Major depressive disorder (MDD) is clinically, and likely pathophysiologically, heterogeneous. A potentially fruitful approach to parsing this heterogeneity is to focus on promising endophenotypes. Guided by the NIMH Research Domain Criteria initiative, we used source localization of scalp-recorded EEG resting data to examine the neural correlates of three emerging endophenotypes of depression: neuroticism, blunted reward learning, and cognitive control deficits. Data were drawn from the ongoing multi-site EMBARC study. We estimated intracranial current density for standard EEG frequency bands in 82 unmedicated adults with MDD, using Low-Resolution Brain Electromagnetic Tomography. Region-of-interest and whole-brain analyses tested associations between resting state EEG current density and endophenotypes of interest. Neuroticism was associated with increased resting gamma (36.5-44 Hz) current density in the ventral (subgenual) anterior cingulate cortex (ACC) and orbitofrontal cortex (OFC). In contrast, reduced cognitive control correlated with decreased gamma activity in the left dorsolateral prefrontal cortex (dlPFC), decreased theta (6.5-8 Hz) and alpha2 (10.5-12 Hz) activity in the dorsal ACC, and increased alpha2 activity in the right dlPFC. Finally, blunted reward learning correlated with lower OFC and left dlPFC gamma activity. Computational modeling of trial-by-trial reinforcement learning further indicated that lower OFC gamma activity was linked to reduced reward sensitivity. Three putative endophenotypes of depression were found to have partially dissociable resting intracranial EEG correlates, reflecting different underlying neural dysfunctions. Overall, these findings highlight the need to parse the heterogeneity of MDD by focusing on promising endophenotypes linked to specific pathophysiological abnormalities.
AB - Major depressive disorder (MDD) is clinically, and likely pathophysiologically, heterogeneous. A potentially fruitful approach to parsing this heterogeneity is to focus on promising endophenotypes. Guided by the NIMH Research Domain Criteria initiative, we used source localization of scalp-recorded EEG resting data to examine the neural correlates of three emerging endophenotypes of depression: neuroticism, blunted reward learning, and cognitive control deficits. Data were drawn from the ongoing multi-site EMBARC study. We estimated intracranial current density for standard EEG frequency bands in 82 unmedicated adults with MDD, using Low-Resolution Brain Electromagnetic Tomography. Region-of-interest and whole-brain analyses tested associations between resting state EEG current density and endophenotypes of interest. Neuroticism was associated with increased resting gamma (36.5-44 Hz) current density in the ventral (subgenual) anterior cingulate cortex (ACC) and orbitofrontal cortex (OFC). In contrast, reduced cognitive control correlated with decreased gamma activity in the left dorsolateral prefrontal cortex (dlPFC), decreased theta (6.5-8 Hz) and alpha2 (10.5-12 Hz) activity in the dorsal ACC, and increased alpha2 activity in the right dlPFC. Finally, blunted reward learning correlated with lower OFC and left dlPFC gamma activity. Computational modeling of trial-by-trial reinforcement learning further indicated that lower OFC gamma activity was linked to reduced reward sensitivity. Three putative endophenotypes of depression were found to have partially dissociable resting intracranial EEG correlates, reflecting different underlying neural dysfunctions. Overall, these findings highlight the need to parse the heterogeneity of MDD by focusing on promising endophenotypes linked to specific pathophysiological abnormalities.
UR - http://www.scopus.com/inward/record.url?scp=84949625118&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84949625118&partnerID=8YFLogxK
U2 - 10.1038/npp.2015.165
DO - 10.1038/npp.2015.165
M3 - Article
C2 - 26068725
AN - SCOPUS:84949625118
SN - 0893-133X
VL - 41
SP - 454
EP - 463
JO - Neuropsychopharmacology
JF - Neuropsychopharmacology
IS - 2
ER -